An interventional study of DeepTms in Tinnitus and Tinnitus, Bilateral, sponsored by University of Regensburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by University of Regensburg · Not applicable, Interventional, and Treatment
Study of the efficacy of different H-coils in chronic tinnitus. Hypothesis: Active Deep repetitive transcranial magnetic stimulation deeprTMS reduces tinnitus distress more effectively than placebo stimulation.
Randomized, placebo-controlled, parallel-group study with three treatment arms; additional comparison with a historical rTMS control group.
A two-week treatment study is planned to investigate the effectiveness of different deepTMS coils in the treatment of tinnitus. The study plans to enroll 60 patients with chronic subjective tinnitus. Recruitment will take place primarily through the affiliated interdisciplinary Tinnitus Center in Regensburg, as well as through posters or flyers at private practice physicians' offices and hearing aid specialists. After successful screening, standard audiological measurements (hearing threshold, tinnitus matching, etc.) and verification of the inclusion and exclusion criteria, study participants will be randomized into one of three treatment groups, each consisting of 20 patients: (1) 18 Hz deepTMS with the H1 coil; (2) 1 Hz deepTMS with the H4 coil; (3) 18 Hz placebo deepTMS with the H7 coil.
Two groups receive active deepTMS treatment, while the third group receives a placebo stimulation. The RCT version of the BrainsWay H7 coil is used for the placebo treatment. The placebo coil is integrated into the same stimulation helmet as the active treatment coil. The placebo stimulation generates acoustic and somatosensory stimuli comparable to those of the active stimulation but does not induce an electric field strong enough for therapeutic cortical stimulation.
The study plans to compare the H1 coil with the H4 coil. Furthermore, the treatment effects will be compared with a placebo treatment as well as with a matched historical control group of patients who were treated with conventional left temporal low-frequency rTMS at the Center for Neuromodulation at the University of Regensburg. The treatment phase corresponds to a standard rTMS treatment for tinnitus and consists of 10 weekday stimulation sessions over two weeks, with 2,000 pulses per session. Before treatment begins, each patient's individual resting motor threshold (RMT) is determined; this is used to set the stimulation intensity for the treatment. The stimulation intensity is gradually increased over the course of the first three treatment sessions from 100% to a maximum of 120% of the RMT. If the stimulation is perceived by the patients as too unpleasant or painful, the intensity is not increased further; treatment continues at the intensity level individually tolerated by each patient. Before and after the 2-week treatment period, patients are given several standardized tinnitus and health questionnaires, and standard audiological measurements are performed. In addition, a follow-up visit is scheduled ten weeks after the end of treatment to assess any potential lasting effects of the treatment. The following questionnaires are used:
There are no plans to calculate the required sample size, as only a single-case trial using deepTMS for tinnitus has been conducted to date. In addition, different coil geometries are used compared to conventional TMS studies. Therefore, it is difficult to estimate the potential effect size.
421 studies on the registry are indexed under Tinnitus; 88 are open to participants now.
This study's planned enrollment of 60 is close to the median of 59 across 346 interventional studies indexed under Tinnitus.
Browse Tinnitus studies →University of Regensburg is the lead sponsor of 71 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
18 Hz, 2000 pulses
Device: DeepTms
1 Hz, 2000 pulses
Device: DeepTms
18 Hz, 2000 pulses placebo
Device: DeepTms
2 weeks deepTMS with different H-coils, 2000 pulses per session, Follow Up 10 weeks after treatment end
Changes in Tinnitus Burden
Changes in Tinnitus Burden Measured Using the Tinnitus Handicap Inventory (THI) from Baseline to the End of Treatment, Including Group Comparisons. The THI consists of 25 items designed to evaluate the perceived impact of tinnitus on an individual's daily life. Each item provides three response options: 'No', 'Sometimes' and 'Yes', which are scored as 0, 2 and 4 points respectively. The total THI score is obtained by summing the scores of all items, resulting in a score that ranges from 0 to 100, with higher scores indicating greater perceived handicap due to tinnitus.
Time frame: 12 weeks: from enrollment to the end of treatment after two weeks, plus Follow Up after 10 weeks
Tinnitus Functional Index (TFI)
Changes in TFI: The TFI measures the functional impact of tinnitus and consists of 25 items. It includes 8 subscales: cognitive interference, auditory perceptual difficulties, intrusiveness, sleep disturbances, disturbances of relaxation, quality of life impairment, emotional distress, and reduced sense of control. The total score ranges from 0 and 100. A lower score indicates greater perceived distress due to tinnitus.
Time frame: 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks
Tinnitus loudness
short-term changes in tinnitus loudness, ranging from 0% to 200% (0%=no tinnitus perception, 50% = half of the usually perceived tinnitus loudness, 100% usually perceived tinnitus loudness, 200%=twice as loud as usually perceived tinnitus loudness
Time frame: 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks
Clinical Global Inventory - Improvement Scale
Within 1 question, patients are asked to rate the overall improvement of their tinnitus complaints compared to before the treatment has started on a 7-point Likert scale (1-"very much better," 2-"much better," 3-"minimally better," 4-"no change," 5-"minimally worse," 6-"much worse," 7-"very much worse").
Time frame: end of treatment after two weeks, plus Follow Up after 10 weeks
Mini-Tinnitus Questionnaire (Mini-TQ)
The Mini-TQ is a validated, 12-item patient-reported outcome measure designed to assess tinnitus-related psychological distress and its impact on daily life. Each item is scored on a 3-point scale: true (2 points), partly true (1 point), or not true (0 points), yielding a total score of 0-24, with higher scores indicating greater tinnitus-related distress.
Time frame: 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks
Major Depression Inventory (MDI)
The MDI is a validated 10-item self-report questionnaire assessing depressive symptoms. Items are rated from 0 (at no time) to 5 (all the time). For items 8 and 10, the higher sub-item score is used. The total score ranges from 0-50, with higher scores indicating greater depressive symptom severity.
Time frame: 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks
Tinnitus Analogue Scales
Participants rate the loudness of their tinnitus (0-not at all loud; 10-extremely loud), the tinnitus-induced discomfort (0-no discomfort; 10-severe discomfort), annoyance (0-not at all annoying; 10-extremely annoying), unpleasantness (0-not at all unpleasant; 10-extremely unpleasant) as well as the possibility to ignore their tinnitus (0-very easy to ignore; 10-impossible to ignore) on a Visual Analog Scale (VAS).
Time frame: 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks
World Health Organization-Quality of Life instrument (WHOQOL-BREF)
A 26-item validated, self-report questionnaire assessing quality of life across four domains: physical health (items 3, 4, 10, 15-18), psychological health (items 5-7, 11, 19, 26), social relationships (items 20-22), and environment (items 8, 9, 12-14, 23-25). Items 1 and 2 assess overall quality of life and general health, respectively. Scoring: Items are rated on a 5-point scale (1-5). Domain scores are transformed to a 4-20 or 0-100 scale, with higher scores indicating better quality of life. Items 3, 4, and 26 are reverse-scored.
Time frame: 12 weeks: from enrollment to end of treatment after 2 weeks, plus Follow Up after 10 weeks
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.
Of 129 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 27 months is above that.
Counting every sponsor, half of 147 studies reached it within 17 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Regensburg